Semaglutide Treatment in Type 1 Diabetes

Inclusion Criteria: * Type 1 Diabetes for more than 3 years * BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis Exclusion Criteria: * Treated with GLP1-RAs within last 6 months * Known intolerance for semaglutide * Other forms of diabetes * Pregnant or nursing women * Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives * Liver disease with elevated plasma alanine aminotransferase (ALT) \> five times and plasma aspartate aminotransferase (AST) \> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive) * Acute or chronic pancreatitis * Cancer, unless in complete remission for \> 5 years or unless basocellular carcinomas * History of thyroid adenoma or carcinoma * Alcohol/drug abuse * Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation * Receipt of an investigational drug within 30 days prior to visit 0 / Simultaneous participation in any other clinical intervention trial